Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
about
Delayed anaphylaxis to alpha-gal, an oligosaccharide in mammalian meat.Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsCurrent advances in immunotherapy for pancreatic cancerAlloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicitySerology in the 21st century: the molecular-level analysis of the serum antibody repertoireCarbohydrate-mimetic peptides for pan anti-tumor responsesCharacteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)Pneumococcal Polysaccharide Vaccination Elicits IgG Anti-A/B Blood Group Antibodies in Healthy Individuals and Patients with Type I Diabetes MellitusNatural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?Tick-host conflict: immunoglobulin E antibodies to tick proteins in patients with anaphylaxis to tick biteIgE-based immunotherapy of cancer: challenges and chances.Lectin-reactive anti-α-gal in patients with Crohn's disease: correlation with clinical phenotypesIncrease in anti-Gal IgM level is associated with early graft failure in intraportal porcine islet xenotransplantation.The quantity and quality of α-gal-specific antibodies differ in individuals with and without delayed red meat allergyBioengineering Hearts: Simple yet Complex.α-Gal Nanoparticles in Wound and Burn Healing Acceleration.Protein-based matrix interferences in ligand-binding assays.Acceleration of wound healing by α-gal nanoparticles interacting with the natural anti-Gal antibody.Generation of GGTA1 Mutant Pigs by Direct Pronuclear Microinjection of CRISPR/Cas9 Plasmid Vectors.Dissociation between anti-porcine albumin and anti-Gal antibody responses in non-human primate recipients of intraportal porcine islet transplantation.Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.Defining Natural Antibodies.Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.Characterization of immunogenic Neu5Gc in bioprosthetic heart valves.Efficient and regioselective synthesis of globotriose by a novel α-galactosidase from Bacteroides fragilis.Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection.A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".Regenerative immunology: the immunological reaction to biomaterials.Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.Prevalence of type I sensitization to alpha-gal in forest service employees and hunters: Is the blood type an overlooked risk factor in epidemiological studies of the α-Gal syndrome?IgE antibodies to alpha-gal in the general adult population: relationship with tick bites, atopy, and cat ownership.Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
P2860
Q26775972-563F7D1C-9541-465E-AF54-DFD591963C0EQ26777542-EA28A9A9-2571-48F1-AAFD-7FCC7744F13BQ26781538-229C8EC3-A1BA-4058-827D-BD5513B7D5ECQ26830170-D984B20D-B251-4A9F-9E25-29041BB4092DQ26866323-F8D11B2C-3101-45B5-9D2E-5625D3BAC636Q26997997-1E3452E7-2CE7-466B-8021-43B64F481D92Q27023624-EF5A4446-DDFC-434E-8F14-FD274A850AD6Q28084522-BED99F19-C1BD-429C-8FE4-1E33B8CDEDF7Q28394046-56C45B6E-70B7-4A11-A93C-329B49FD0D56Q30248270-636EF3E4-372A-4098-BD26-2A52AE059DB6Q33591274-4C2CDB80-C1E8-4EAA-8DEB-3C3324F86447Q33619979-2D20B43F-55C3-44DE-A9B0-67272273E710Q33956556-F72C10DF-0BC4-48CA-8757-B8E0CE8ED320Q36083701-CE1FA92F-2170-48DF-B9D2-FA8D129122A3Q37593756-00BC4A95-CAA7-4CFE-BA64-37FE62F7D0ADQ37650656-6B6C1A6E-790C-443B-BD97-BE1A1D9EBACEQ37695144-91D8B13D-8982-42F5-A012-AD603EFB10E8Q38211931-88BAB447-6919-482F-B06E-A789CC13A4E1Q38299403-3C47D331-C6E5-40B6-9CDE-6D823C916BA5Q38796503-5C744879-A4D2-4E3D-9C44-72F2EE2D2589Q38914165-E46FE4AC-854A-4A15-8ECC-D1BD6B8399D2Q39294509-7670DD65-71A0-4F4F-8622-0C6AD43358B0Q40097746-5871C5EB-6568-44AC-A0ED-1271ACCF4649Q40488832-4691F686-599B-4302-9CC5-296E4A5FBF0FQ40545748-76C2EE1B-CF96-4372-A115-A22AA2D17F05Q40738743-E16C7CE4-52D9-4893-B3C1-6227346A2B38Q41894108-CB343803-265F-4F8F-976C-E44C26127888Q43214125-EEC40097-3DB6-4505-82CC-A2BCE4D86D81Q46181413-B148D426-2981-4C3A-A846-F1598BB354FAQ46911010-6F7E835E-DC7F-404C-AD42-B8DFDB042ED2Q47552836-BA2B10F0-EC2B-436D-BB59-18E31B81B8E6Q48265453-5635DA95-6370-4375-9CD2-36263E4CD525Q50473371-70C3EE64-F7E3-42A6-BABF-61F98DEF1592Q51469542-D30C2698-FF1A-4566-AC55-996731DA4F62
P2860
Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@ast
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@en
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@nl
type
label
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@ast
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@en
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@nl
prefLabel
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@ast
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@en
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@nl
P2860
P3181
P356
P1433
P1476
Anti-Gal: an abundant human na ...... ogeneses and clinical benefits
@en
P2093
Uri Galili
P2860
P3181
P356
10.1111/IMM.12110
P407
P577
2013-09-01T00:00:00Z